98. Heart Protection Study (HPS) Collaborative Group. MRC/BHF Heart Protection
Study of cholesterol lowering with simvastatin in 5963 people with diabetes.
Lancet 200. - Vol. 361 (14). - P.2005-2016.
99. Hernandez, C. Effects of hypolipidemic treatment on serum markers of vascular
inflammation in dyslipidemic men / C. Hernandez, A. Lecube, G. Barbera, et al.
// Med Sci Monit. - 2003. - Vol. 9. - CR114-CR119.
100. Hill, S.A. Reverse cholesterol transport - a review of the process and its clinical
implications / S.A. Hill, M.J. McQueen // Clin Biochem. - 1997. - Vol. 294. -
P.829-834.
101. Hooper, L. Dietary advice,modification or supplementation aimed at lipid
lowering for prevention of cardiovascular disease with and without ischaemic
heart disease / L. Hooper, C. Summerbell, J. Higgins, et al. // In: The Cochrane
Library, Issue 4, 2000. - Oxford.
102. James, W. The SCOUT study: risk benefit profile of sibutramine in overweight
high-risk cardiovascular patients / W.James // Eur Heart J. - 2005. -
Suppl.7(Suppl. L). - L44-48.
103. Jayakumar, T. Antioxidant activity of the oyster mushroom, Pleorotus ostreatus,
on CCI(4) - indused liver injury in rats / T.Jayakumar, E. Ramesh,P. Gfraldine //
Food. Chem. Toxicol. - 2006.
- Vol. 44( 12). - P. 1989-1996.
104. Kastelein, J. Simvastatin with or without ezetimibe
in
familial
hypercholesterolaemia / J. Kastelein, F. Akdim // New Engl J Med. - 2008. -
Vol. 3 581 ,- P.431-443.
105. Keating, G.M. Fenofibrate: a review of its use in primary dyslipidaemia, the
metabolic syndrome and type 2 diabetes mellitus / G.M. Keating, K.F. Croom //
Drugs. - 2007. - Vol. 67(1). - P. 121-153.
106. Kelley, D.E. Interaction between glucose and free fatty acid metabolism in
human skeletal muscle / D.E. Kelley, M. Mokan, J.A. Simoneau, et al. // J Clin
Invest. - 1993. - Vol. 92. - P.9I-98.
107. Keys, A. Diet and the epidemiology of coronary heart disease // A. Keys //
JAMA. - 1957. - Vol. 164(17).- P . 1912-1919.
94
